PHOMMALONE NGUYEN: Open Payments
NPI 1851756589 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,636 in 25 payments from 18 companies in 2025. Trend: 2023 $1,919 · 2024 $2,731 · 2025 $2,636
Food & beverage: $2,636
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 3 | $375 |
| GENZYME CORPORATION | 3 | $358 |
| ABBVIE INC. | 2 | $215 |
| GlaxoSmithKline, LLC. | 2 | $157 |
| Averitas Pharma Inc. | 2 | $150 |
| Ipsen Biopharmaceuticals, Inc | 1 | $133 |
| AstraZeneca Pharmaceuticals LP | 1 | $122 |
| Phathom Pharmaceuticals, Inc. | 1 | $114 |
| Medtronic, Inc. | 1 | $113 |
| ViiV Healthcare Company | 1 | $113 |
Products named: QUTENZA, Yeztugo, IQIRVO, MAVYRET, TEZSPIRE, KEVZARA, VOQUEZNA, INTELLIS ADAPTIVESTIM.
Industry payments across TX — which companies pay providers there.
